Novo Taps Veteran as CEO to Tackle Unprecedented CompetitionBy
Joergensen joined Danish drugmaker as economist 25 years ago
Novo under pressure from rival drugs in its largest market
The man appointed to succeed Lars Rebien Soerensen as Novo Nordisk A/S’s chief executive officer says to expect continuity, but a challenging diabetes market may force him to diverge from Soerensen’s time-tested path.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.